Parnassus Investments LLC Has $37.90 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Parnassus Investments LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 199,552 shares of the medical research company’s stock after selling 7,779 shares during the period. Parnassus Investments LLC owned 0.12% of IQVIA worth $37,903,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Asset Dedication LLC grew its stake in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH bought a new position in IQVIA during the second quarter valued at approximately $39,000. J.Safra Asset Management Corp grew its position in IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares in the last quarter. Rothschild Investment LLC increased its stake in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC lifted its stake in shares of IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 189 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $242.70 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.05. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a fifty day simple moving average of $224.37 and a 200 day simple moving average of $200.19. The firm has a market capitalization of $41.33 billion, a price-to-earnings ratio of 33.29, a PEG ratio of 2.47 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the company posted $2.84 EPS. The business’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Barclays set a $230.00 price target on IQVIA in a research report on Monday, December 15th. Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $249.19.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.